Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676430 | 0.81 | L3MBTL1 (0.35) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL3811684 | 0.76 | HSD11B1 (0.36) | ALDH1A1CYP1A2 | |
| SCHEMBL3811681 | 0.74 | BACE1 (0.35) | RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3683551 | 0.70 | NPC1 (0.31) | NPC1SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL3611287 | 0.67 | HTR7 (0.35) | RAB9ASMN1; SMN2TP53KDM4EHSD17B10 | |
| SCHEMBL3681805 | 0.66 | NUDT1 (0.32) | — | |
| SCHEMBL24677590 | 0.66 | KDM4E (0.50) | GRM4ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL2039527 | 0.66 | SMN1; SMN2 (0.62) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29496935 | 0.66 | SMN1; SMN2 (0.62) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7196588 | 0.65 | KDM4E (0.54) | GRM4ADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2077270-B1 | Transition metal complexes, and catalysts compositions for preparing ethylene homopolymers or copolymers | SK INNOVATION CO LTD (KR) | 2013-03-20 | — | — | EP | disclosed |
| US-7847039-B2 | transition metal catalyst having a cyclopentadiene derivative and an aryl oxide ligand with a heteroaryl derivative at the ortho-position as polymerization catalysts for high molecular weight ethylene homo- or copolymers; e.g. (dichloro)(pentamethylcyclopentadienyl)(2-thiophen-2'-yl)phenoxy)titanium(IV) | SK ENERGY CO., LTD. (KR) | 2010-12-07 | — | — | US | disclosed |
| US-20090176948-A1 | Transition metal complexes, and catalysts compositions for preparing ethylene homopolymers or copolymers | SABIC SK NEXLENE COMPANY PTE. LTD. (SG) | 2009-07-09 | — | — | US | disclosed |
| EP-2077270-A1 | Transition metal complexes, and catalysts compositions for preparing ethylene homopolymers or copolymers | SK Energy Co., Ltd. (KR) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176948-A1 | Transition metal complexes, and catalysts compositions for preparing ethylene homopolymers or copolymers | ETV6, OXER1, AP1M1 | GRM4 888/4885ADRA2A 4606/4885ADRA2B 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.